Highlights in Renal Cell Carcinoma: The Evolving Landscape of Adjuvant Therapy (2018)
The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:
- Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area.
- Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer.
- Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologists.
After participating in this activity, the learner will be able to:
- Debate the elements of disagreement regarding the use of adjuvant therapy for patients with renal cell carcinoma.
- Discuss the evolving landscape of adjuvant therapy for the treatment of renal cell carcinoma.
William C Huang, MD, FACS
NYU Langone Heath
Disclosures: Photocure: Scientific Study or Trial; Karl Storz: Scientific Study or Trial; Intuitive; Meeting Participant or Lecturer
Viraj Master MD, PhD, FACS
Disclosures: Nothing to disclose
Method of Participation
To claim CME credit/hours of participation, the learner must view the video, complete the post-test passing with 80% accuracy and submit the activity evaluation.
Estimated time to complete this activity: 1.00 hour
Release Date: May 21, 2018
Expiration Date: May 21, 2020
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1.00 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
This educational activity is supported by an independent educational grant from Pfizer, Inc.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation